O
DICE

OrbiMed’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

OrbiMed’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-440,000
Closed -$14.4M – 179
2021
Q3 		$14.4M Buy
+440,000
New +$15M 0.16% 112

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed's DICE Position: Q4 2021 in Review

OrbiMed sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q4 2021, closing a stake of 440,000 shares — an estimated $14.4M sold.

OrbiMed first reported a position in DICE in Q3 2021 and held it in 1 quarter. The position peaked at $14.4M in Q3 2021. 69 funds tracked by Wall St. Rank hold DICE as of Q4 2021.

  • OrbiMed reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • OrbiMed sold 440,000 DICE Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $14.4M.
  • OrbiMed first reported a position in DICE Therapeutics, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • OrbiMed's DICE Therapeutics, Inc. Common Stock position peaked at $14.4M in Q3 2021.
  • 69 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q4 2021.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.